Revenue: The sum of all revenue fields included for a company's operating activities.
NewAmsterdam Pharma Company N.V. (NAMS) had Revenue of $45.56M for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
|
Revenue |
$45.56M |
$-241.60M |
|
-- |
|
$45.56M |
|
$221.85M |
|
$-176.29M |
|
$-65.31M |
|
$-241.60M |
|
$-241.60M |
|
$-241.60M |
|
$-241.60M |
|
$-241.60M |
|
$-241.60M |
|
$-176.29M |
|
$-176.18M |
|
94.36M |
|
94.36M |
|
$-2.56 |
|
$-2.56 |
|
| Balance Sheet Financials | |
$863.41M |
|
$0.24M |
|
$1.21M |
|
$864.62M |
|
$106.92M |
|
-- |
|
$0.20M |
|
$107.12M |
|
$757.50M |
|
$756.97M |
|
$757.50M |
|
108.06M |
|
| Cash Flow Statement Financials | |
$-158.56M |
|
$-62.85M |
|
$659.51M |
|
$340.45M |
|
$771.74M |
|
$431.29M |
|
$33.62M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
8.08 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-386.91% |
|
-386.91% |
|
-386.66% |
|
-530.25% |
|
-530.25% |
|
$-159.24M |
|
-- |
|
-- |
|
-- |
|
0.05 |
|
-- |
|
9.20 |
|
39.66 |
|
-31.89% |
|
-31.92% |
|
-27.94% |
|
-31.89% |
|
$7.01 |
|
$-1.69 |
|
$-1.68 |
|